Answers are grounded in this paper and cite their sources.
Background Radiographic progression (rPD) at castration-resistant prostate cancer (CRPC) diagnosis remains poorly characterized in real-world settings. We assessed its prognostic impact and the clinical features of patients with rPD in real-world de novo metastatic castration-sensitive prostate cancer (mCSPC). Methods We retrospectively analyzed 330 patients with de novo mCSPC who progressed to CRPC from two multi-institutional cohorts: a conventional androgen deprivation therapy or combined androgen blockade (ADT/CAB) cohort ( n = 272) and an upfront intensification cohort ( n = 58). At CRPC diagnosis, patients were categorized as having prostate-specific antigen (PSA)-only progression or PSA + rPD. Post-CRPC overall survival (OS) was evaluated using Kaplan–Meier and Cox proportional hazards models, while rPD-associated characteristics were examined using logistic regression. Results Across both cohorts, patients with PSA + rPD had significantly shorter post-CRPC OS than those with PSA-only progression (ADT/CAB: 21 vs. 44 months, P < 0.001; upfront: 14 vs. 24 months, P = 0.008). Univariate Cox regression confirmed the adverse prognostic impact of rPD (hazard ratios 2.25 [95% CI 1.53–3.29] and 2.49 [95% CI 1.22–5.07]). Lower baseline PSA was significantly associated with rPD in the upfront cohort (odds ratio [OR] 0.30, 95% CI 0.12–0.75, P = 0.010), with a non-significant trend in the ADT/CAB cohort (OR 0.71, 95% CI 0.47–1.06, P = 0.092). Conclusion Radiographic progression at CRPC transition predicts poor post-CRPC survival in real-world mCSPC patients, regardless of initial treatment. Lower baseline PSA may identify patients at increased risk of rPD, supporting careful radiographic monitoring at CRPC transition.
No takes yet. Share an insight, caveat, or question.
Fujimoto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: